Abstract
Background Sleep disorders are common among individuals with epilepsy, often leading to disturbances in sleep patterns and architecture. Certain anti-seizure medications adversely affect sleep independently of their anti-seizure effects. Objective This study aims to examine the impact of perampanel (PER) on sleep disorders in patients with epilepsy. Methods The effects of adjunctive PER therapy on circadian rhythm and daytime sleepiness were evaluated in epilepsy patients with comorbid sleep disorders. Twenty-one eligible patients were included, excluding those with liver failure or psychological disorders. This pilot case series assessed participants using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale. PER blood concentrations were measured. Patients were selected based on baseline PSQI scores ≥6 (mean 11.57 ± 2.77). Results After 3 months of PER administration, the mean global PSQI score significantly improved to 6.71 ± 5.00 (p<0.01). Improvements were observed in PSQI components: C1 (sleep quality), C2 (sleep latency), and C6 (frequency of sleep medication use). A strong positive correlation was found between changes in PSQI scores (delta-PSQI = post-PER − pre-PER score) and PER blood concentrations (r = 0.71, p<0.01). Conclusion Adjunctive PER therapy significantly improved subjective sleep quality in epilepsy patients with comorbid sleep disorders. The correlation between the magnitude of improvements and PER blood concentration suggests a dose–response relationship. These findings indicate that PER may be a beneficial therapeutic option for managing sleep disturbances in this population and support the need for further investigation in larger, controlled studies.